EFECTIVIDAD DE LA TOXINA BOTULÍNICA TIPO A EN EL MANEJO DE LA CADERA ESPÁSTICA DE NIÑOS CON PARÁLISIS CEREBRAL / EFFECTIVENESS OF THE TOXIN BOTULINUM TYPE A IN THE DRIVING OF THE HIP CHILDREN'S SPASTICS WITH CEREBRAL PALSY

La espasticidad es uno de los principales factores de riesgo que predispone a la luxación de cadera en los niños con parálisis cerebral (PC). La aplicación de toxina botulínica (BTX A) en los músculos aductores de caderas reduce este riesgo

Spasticity is one of the main risk factors predisposing to hip dislocation in children with cerebral palsy (CP), Botulinum toxin A (BTX A) injection in hip adductor muscles reduces this risk

Revisión sistemática y coste efectividad del tratamiento con abobotulinumtoxinA Para la espasticidad post-ictus en comparación con fisioterapia / Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy

Objective Post-stroke spasticity (PSS) is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone. Methods A systematic literature review in EMBASE (including Medline and PubMed), Scopus, and other sources (Google Scholar) was conducted. Articles of all types, providing information on the costs and/or effectiveness measures for the current treatments of PSS in adults were included. The synthesis of information from the review provided the parameters for the design of a cost-effectiveness analysis of the mentioned treatment of interest. The societal perspective was compared to a perspective where only direct costs were observed. Results In total, 532 abstracts were screened. Full information was revised from 40 papers and 13 of these were selected as core papers for full data extraction. Data from the core publications formed the basis for the development of a cost-effectiveness model. In all the included papers physiotherapy was the best supportive care treatment (SoC)... (AU)

Antecedentes La espasticidad post-ictus es una enfermedad común que afecta a los adultos y causa una carga grave a los pacientes que la padecen. El objetivo de la revisión fue realizar un análisis coste-efectividad (ACE) del tratamiento de la espasticidad post-ictus, en adultos, con abobotulinumtoxinA (aboBoNT-A) en comparación con el tratamiento convencional, basado en los resultados de una revisión sistemática de la literatura. Dado que este tratamiento se proporciona siempre al mismo tiempo que el tratamiento convencional, el ACE se realizó del tratamiento aboBoNT-A con el tratamiento convencional, en comparación con recibir únicamente el tratamiento convencional. Métodos Se realizó una revisión sistemática de la literatura en EMBASE (incluyendo Medline y Pubmed), Scopus y otras fuentes (Google Scholar). Se incluyeron artículos de todo tipo que proporcionaran información sobre los costes y/o las medidas de efectividad de los tratamientos actuales del PSS en adultos. La síntesis de la información de la revisión proporcionó los parámetros para el diseño de un análisis coste-efectividad del mencionado tratamiento de interés. Se comparó la perspectiva social con una perspectiva donde solo se observaron los costes directos del tratamiento. Resultados Se revisaron un total de 532 resúmenes. Se revisó la información completa de 40 artículos y se seleccionaron 13 artículos para la extracción completa de datos. La información de estos documentos se sintetizó y utilizó para desarrollar un modelo de coste-efectividad. En todos los artículos incluidos se identificó el tratamiento con fisioterapia como el tratamiento convencional principal... (AU)

Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy. / [Artículo traducido] Revisión sistemática y coste-efectividad del tratamiento con abobotulinumtoxinA para la espasticidad postictus en comparación con la fisioterapia.

OBJECTIVE: Post-stroke spasticity is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone. METHODS: A systematic literature review in EMBASE (including Medline and PubMed), Scopus, and other sources (Google Scholar) was conducted. Articles of all types, providing information on the costs and/or effectiveness measures for the current treatments of post-stroke spasticity in adults were included. The synthesis of information from the review provided the parameters for the design of a CEA of the mentioned treatment of interest. The societal perspective was compared to a perspective where only direct costs were observed. RESULTS: In total, 532 abstracts were screened. Full information was revised from 40 papers and 13 of these were selected as core papers for full data extraction. Data from the core publications formed the basis for the development of a cost-effectiveness model. In all the included papers physiotherapy was the best supportive care treatment. The cost-effectiveness analysis showed that even in the most conservative scenario, assuming the worst case scenario, the probability of a cost per quality-adjusted life-year (QALY) gained below €40,000, for aboBoNT-A together with physiotherapy is above 0.8, and with certainty below €50,000/QALY when either a direct costs, or a societal perspective was taken. On average, the probabilistic model obtains a negative mean incremental cost-effectiveness ratio of around -15,000 €/QALY. CONCLUSION: The cost-effectiveness analyses show that aboBoNT-A together with physiotherapy would be a cost-effective treatment compared with physiotherapy alone, independently of the perspective considered.

Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy.

OBJECTIVE: Post-stroke spasticity (PSS) is a common complication in stroke survivors, causing severe burden to patients living with it. The aim of this review was to conduct a cost-effectiveness analysis (CEA) of the treatment of post-stroke spasticity, in adults, with abobotulinumtoxinA compared to the best supportive care, based on results from a systematic literature review. Given that abobotulinumtoxinA (aboBoNT-A) is always accompanied by the best supportive care treatment, the CEA compared aboBoNT-A plus the best supportive care with the best supportive care alone. METHODS: A systematic literature review in EMBASE (including Medline and PubMed), Scopus, and other sources (Google Scholar) was conducted. Articles of all types, providing information on the costs and/or effectiveness measures for the current treatments of PSS in adults were included. The synthesis of information from the review provided the parameters for the design of a cost-effectiveness analysis of the mentioned treatment of interest. The societal perspective was compared to a perspective where only direct costs were observed. RESULTS: In total, 532 abstracts were screened. Full information was revised from 40 papers and 13 of these were selected as core papers for full data extraction. Data from the core publications formed the basis for the development of a cost-effectiveness model. In all the included papers physiotherapy was the best supportive care treatment (SoC). The cost-effectiveness analysis showed that even in the most conservative scenario, assuming the worst case scenario, the probability of a cost per quality-adjusted life-year (QALY) gained below €40,000, for aboBoNT-A together with physiotherapy is above 0.8, and with certainty below €50,000/QALY when either a direct costs, or a societal perspective was taken. On average, the probabilistic model obtains a negative mean incremental cost-effectiveness ratio of around -15,000 €/QALY. CONCLUSION: The cost-effectiveness analyses show that aboBoNT-A together with physiotherapy would be a cost-effective treatment compared with physiotherapy alone, independently of the perspective considered.

Prevalence, Onset, Evolution, and Prediction of Spasticity Poststroke: A Longitudinal Study / Prevalencia, inicio, evolución y predicción de la espasticidad posterior a un ACV: un estudio longitudinal / Prevalência, início, evolução e previsão de espasticidade após AVC: um estudo longitudinal

Introduction: Because of the the complex physiopathology of spasticity, it is distinguished as one of the most significant positive clinical signs of upper motor neuron syndrome, constituting a clinical feature that has great impact in the neurorehabilitation setting. Thus, the current study aimed to determine the prevalence, onset, evolution, and prediction of spasticity after a stroke. Materials and Methods: A correlational, longitudinal design was used. A total of 136 patients were evaluated at the following times: 10 days (T1), 3 months (T2), and 12 months (T3) poststroke. The initial evaluation included sociodemographic and clinical data (T1). Muscle tone was measured (T1, T2, and T3) using the Modified Ashworth Scale. Results: The prevalence of poststroke spasticity in the elbow was 37.5 % at T1 and 57.4 % at T2 and T3. Among patients with motor damage, the onset of spasticity occurred at T1 in 44.7 %, between T1 and T2 in 23.7 %, and between T2 and T3 in 0.9 %. Significant predictors of the alteration in muscular tone for at least two of the evaluation times were ethnic self-classification, type, area, extent of stroke, and number of sessions. Conclusions: Spasticity onset occurs during the first 10 days after a stroke. More clinical than sociodemographic variables predicted spasticity.

Introducción: la espasticidad se destaca como uno de los signos clínicos positivos más significativos del síndrome de motoneurona superior, por su compleja fisiopatología, y constituye una característica clí- nica de gran impacto en el ámbito de la neurorrehabilitación. Por lo tanto, el objetivo fue determinar la prevalencia, el inicio, la evolución y la predicción de la espasticidad después de un accidente cerebro- vascular. Materiales y métodos: se utilizó un diseño longitudinal correlacional. Se evaluaron 136 pacientes: 10 días (T1), 3 meses (T2) y 12 meses (T3) pos-ACV. La evaluación incluyó datos sociodemográficos y clínicos (T1) y se midió el tono muscular (T1, T2 y T3) mediante la Escala de Ashworth Modificada. Resultados: la prevalencia en el codo fue del 37.5 % en T1, y del 57.4 % en T2 y T3. Entre los pacientes con daño motor, el inicio de la espasticidad ocurrió en T1 para el 44.7 % de ellos, entre T1 y T2 para el 23.7 % y entre T2 y T3 para el 0.9 %. La autoclasificación étnica, el tipo, el área, la extensión del ictus y el número de sesiones predijeron significativamente la alteración del tono muscular en al menos dos ocasiones. Conclusiones: el inicio de la espasticidad ocurre durante los 10 primeros días después de un ACV. Más variables clínicas que sociodemográficas predijeron espasticidad.

Introdução: a espasticidade destaca-se como um dos sinais clínicos positivos mais significativos da síndrome do neurônio motor superior, devido à sua fisiopatologia complexa, e constitui uma característica clínica de grande impacto no campo da neurorreabilitação. Portanto, nosso objetivo foi determinar a prevalência, início, evolução e predição da espasticidade após o acidente vascular cerebral. Materiais e métodos: foi utilizado um desenho correlacional longitudinal. Foram avaliados 136 pacientes: 10 dias (T1), 3 meses (T2) e 12 meses (T3) pós-AVC. A avaliação incluiu dados sociodemográficos e clínicos (T1) e o tônus muscular (T1, T2 e T3) foi medido por meio da Escala Modificada de Ashworth. Resultados: a prevalência no cotovelo foi de 37,5 % em T1 e 57,4 % em T2 e T3. Entre os pacientes com prejuízo motor, o início da espasticidade ocorreu em T1 em 44,7 % deles, entre T1 e T2 em 23,7 % e entre T2 e T3 em 0,9 % dos pacientes. A autoclassificação étnica, o tipo, a área, a extensão do AVC e o número de sessões predisseram significativamente as anormalidades do tônus muscular em pelo menos duas ocasiões. Conclusões: o início da espasticidade ocorre durante os primeiros 10 dias após o acidente vascular cerebral. Mais variáveis clínicas do que sociodemográficas previram a espasticidade

Botulinum toxin type A infiltration in spasticity and cervical dystonia. Muscle morphology: an overlooked factor.

INTRODUCTION: Botulinum toxin type A is used to treat spasticity and dystonia. However, its relationship with muscle morphology has not been studied. The action mechanism of botulinum toxin is based on the inhibition of acetylcholine release. Therefore, larger doses of toxin would be needed to treat larger muscles. This study aims to establish whether there is a discrepancy between muscle morphology and the botulinum toxin doses administered. METHODS: We dissected, and subsequently measured and weighed, muscles from the upper and lower limbs and the head of a fresh cadaver. We consulted the summary of product characteristics for botulinum toxin type A to establish the recommended doses for each muscle and calculated the number of units infiltrated per gramme of muscle. RESULTS: Different muscles present considerable morphological variability, and the doses of botulinum toxin administered to each muscle are very similar. We observed great variability in the amount of botulinum toxin administered per gramme of muscle, ranging from 0.3 U/g in the biceps femoris to 14.6 U/g in the scalene muscles. The mean dose was 2.55 U/g. The doses administered for nearly all lower limb muscles were below this value. CONCLUSIONS: There are significant differences in morphology between the muscles of the lower limbs, upper limbs, and head, but similar doses of botulinum toxin are administered to each muscle. These differences result in great variability in the number of units of botulinum toxin administered per gramme of muscle.

Desenlaces clínicos y radiológicos del tratamiento quirúrgico de la cadera paralítica en pacientes con parálisis cerebral en Bogotá, Colombia / Clinical and radiological outcomes of surgical treatment for paralytic hip in cerebral palsy patients in Bogotá, Colombia

Introducción. La parálisis cerebral (PC) produce una alteración del tono y del balance muscular que puede generar luxación paralítica de cadera (LPC), especialmente en los pacientes más comprometidos Objetivo. Describir los desenlaces clínicos y radiológicos de los pacientes con PC que recibieron tratamiento quirúrgico de la LPC en el Instituto Roosevelt. Materiales y métodos. Estudio observacional retrospectivo realizado en 92 pacientes entre 4 y 18 años con PC y LPC operados entre 2010 y 2014. Se realizaron análisis bivariados para realizar comparaciones entre los hallazgos clínicos y radiológicos antes de la operación de corrección de la LPC y al finalizar el periodo posoperatorio mediante las pruebas de McNemar, T de student y U de- Mann-Whitney. Resultados. La media de edad fue 7,45 años, el 84,8% de los pacientes tenía PC espástica y el 59,8% fue clasificado en el nivel V del Gross motor function classification system. Se realizaron 155 cirugías en los 92 pacientes, los procedimientos más frecuentes fueron reducción cerrada y osteotomías pélvica, femoral varizante y femoral desrotadora. En el posoperatorio el dolor y la dificultad para realizar el aseo, sedestación y abducción de caderas disminuyeron significativamente (p<0,001). Además, hubo diferencias estadísticas en los índices y ángulos radiológicos pre y posoperatorios. Conclusión: Si bien se encontró una mejoría significativa en los desenlaces clínicos y radiológicos evaluados, los procedimientos reconstructivos y de salvamento predominaron, en detrimento de los preventivos, por lo que es necesario fortalecer los programas de seguimiento y prevención de la LPC y sus complicaciones en la institución para disminuir morbilidad en los pacientes con PC

Introduction: Cerebral palsy (CP) causes an alteration of muscle tone and balance that may lead to paralytic hip dislocation (PHD), especially in the most severely affected patients. Objective: To describe the clinical and radiological outcomes of patients with CP who underwent surgical treatment of PHD at the Instituto Roosevelt. Methodology: Retrospective observational study performed on 92 patients aged 4 to 18 years with CP and PHD operated on between 2010 and 2014. Bivariate analyses were performed to compare clinical and radiological findings before and after the surgery to correct PHD using McNemar's test, Student's t-test, and Mann-Whitney U-test. Results: The mean age was 7.45 years, 84.8% of the patients had spastic CP, and 59.8% were classified at level V of the Gross Motor Function Classification System. A total of 155 surgeries were performed in the 92 patients, the most frequent procedures being closed reduction and pelvic, femoral varus, and femoral derotation osteotomies. After surgery, pain, and difficulty in personal care, sitting and hip abduction decreased significantly (p<0.001). In addition, statistical differences were found between preoperative and postoperative radiological indices and angles. Conclusion: Although a significant improvement was found in the clinical and radiological outcomes evaluated, reconstructive and salvage procedures predominated over preventive ones, thus making it necessary to strengthen follow-up and prevention programs for PHD and its complications in the institution in order to reduce morbidity in patients with CP

Análisis descriptivo de coste de tratamiento de la espasticidad con diferentes tipos de toxina botulínica A, a lo largo de un año / Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A

Introducción: La toxina botulínica A es el tratamiento de elección para la espasticidad localizada. Sin embargo, no se tiene un conocimiento real de su repercusión económica.El objetivo de este trabajo es describir los costes reales del tratamiento de la espasticidad en adultos con toxina botulínica A en una consulta de espasticidad de un Servicio de Rehabilitación, a lo largo de un año.MétodosSe ha realizado la revisión retrospectiva de todos los actos médicos llevados a cabo a lo largo del año 2017. Se han recogido el tipo de toxina utilizado (incobotulinumtoxin A, onabotulinumtoxin A, abobotulinumtoxin A), las unidades inyectadas, la región anatómica y el tiempo transcurrido entre infiltraciones. Se han obtenido los costes de la medicación y los costes indirectos, como los de personal o los fungibles.ResultadosEste es el primer trabajo que describe los costes reales del tratamiento de la espasticidad en adultos con toxina botulínica A en España. En 2017 se realizaron 510 actos de infiltración en 164 pacientes. El coste total de tratamiento de espasticidad en nuestro servicio fue de 116.789,70 €. El coste medio anual por paciente fue 603,64 € para onabotulinumtoxin A, de 642,69 € para abobotulinumtoxin A y de 707,59 € para incobotulinumtoxin A.ConclusionesNuestro estudio económico de actividad clínica real sigue una pauta similar a la descrita en los modelos teóricos publicados en la literatura. Las diferentes características de cada toxina y la imposibilidad de establecer una equivalencia entre las unidades de cada una de ellas impiden la comparación directa de estos costes. (AU)

Introduction: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known.This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year.MethodsWe retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or AAbobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated.ResultsThis is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was €116 789.70. The mean annual cost per patient was €603.64 for onabotulinumtoxin A, €642.69 for abobotulinumtoxin A, and €707.59 for incobotulinumtoxin A.ConclusionsOur economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs. (AU)

Guía clínica para el tratamiento de la espasticidad: consenso y algoritmos / Clinical practice guideline for the treatment of spasticity: Consensus and algorithms

La espasticidad es un fenómeno complejo de expresión clínica extremadamente variable, un proceso dinámico y evolutivo que puede condicionar la funcionalidad y tratamiento del paciente. La recomendación actual de tratamiento temprano persigue evitar su progresión y complicaciones, e implica un planteamiento individualizado basado en un amplio abanico de medidas farmacológicas y no farmacológicas. Esta guía resulta de un foro de especialistas expertos que afrontaron algunas incertezas frecuentes en el proceso de valoración y planteamiento terapéutico como la idoneidad de iniciar tratamiento, consideraciones para iniciar, continuar y cesar el tratamiento con toxina botulínica, tratamientos adyuvantes, el dolor o el seguimiento del paciente espástico. El resultado es un algoritmo de decisión para el abordaje terapéutico de la espasticidad. Tanto el avance científico como el intercambio de experiencia clínica en el que se basa esta guía puede apoyar la toma de decisiones sobre algunas áreas de penumbra que encontramos en la práctica clínica diaria.(AU)

Spasticity is a complex phenomenon of extremely variable clinical expression, a dynamic and evolutionary process that can condition the activity and treatment of the patient. The current recommendation for early treatment aims to avoid progression and complications, and involves an individualized approach based on a wide range of pharmacological and non-pharmacological measures. This guide results from a forum of expert specialists who faced some frequent uncertainties in the assessment process and therapeutic approach of the spastic patient such as the suitability of initiating treatment, considerations for initiating, continuing and ceasing treatment with botulinum toxin, adjuvant treatments, pain or follow-up. The result is one algorithm of decision for the therapeutic approach of spasticity. Both scientific progress and the exchange of clinical experience on which this guide is based, can support decision-making on some areas of gloom that we find in daily practice.(AU)

Current evidence on the potential therapeutic applications of transcranial magnetic stimulation in multiple sclerosis: a systematic review of the literature.

INTRODUCTION: A growing number of studies have evaluated the effects of transcranial magnetic stimulation (TMS) for the symptomatic treatment of multiple sclerosis (MS). METHODS: We performed a PubMed search for articles, recent books, and recommendations from the most relevant clinical practice guidelines and scientific societies regarding the use of TMS as symptomatic treatment in MS. CONCLUSIONS: Excitatory electromagnetic pulses applied to the affected cerebral hemisphere allow us to optimise functional brain activity, including the transmission of nerve impulses through the demyelinated corticospinal pathway. Various studies into TMS have safely shown statistically significant improvements in spasticity, fatigue, lower urinary tract dysfunction, manual dexterity, gait, and cognitive deficits related to working memory in patients with MS; however, the exact level of evidence has not been defined as the results have not been replicated in a sufficient number of controlled studies. Further well-designed, randomised, controlled clinical trials involving a greater number of patients are warranted to attain a higher level of evidence in order to recommend the appropriate use of TMS in MS patients across the board. TMS acts as an adjuvant with other symptomatic and immunomodulatory treatments. Additional studies should specifically investigate the effect of conventional repetitive TMS on fatigue in these patients, something that has yet to see the light of day.

[Clinical practice guideline for the treatment of spasticity: Consensus and algorithms]. / Guía clínica para el tratamiento de la espasticidad: consenso y algoritmos.

Spasticity is a complex phenomenon of extremely variable clinical expression, a dynamic and evolutionary process that can condition the activity and treatment of the patient. The current recommendation for early treatment aims to avoid progression and complications, and involves an individualized approach based on a wide range of pharmacological and non-pharmacological measures. This guide results from a forum of expert specialists who faced some frequent uncertainties in the assessment process and therapeutic approach of the spastic patient such as the suitability of initiating treatment, considerations for initiating, continuing and ceasing treatment with botulinum toxin, adjuvant treatments, pain or follow-up. The result is one algorithm of decision for the therapeutic approach of spasticity. Both scientific progress and the exchange of clinical experience on which this guide is based, can support decision-making on some areas of gloom that we find in daily practice.

Correlação entre espasticidade do membro superior e movimentação da mão no pós-AVC / Correlación entre la espasticidad del miembro superior y el movimiento de la mano post-ACV / Correlation between upper limb spasticity and hand movement after stroke

RESUMO A hemiparesia e a espasticidade são consequências comuns em pacientes que sofreram um acidente vascular cerebral (AVC) e delas decorre a dificuldade do paciente de movimentar o hemicorpo acometido. O objetivo deste estudo foi, assim, verificar a relação da espasticidade no membro superior (MS) com a capacidade de movimentação da mão desses pacientes, a partir de um estudo transversal de delineamento ex-post facto correlacional. Foram avaliados pacientes que realizavam acompanhamento no Ambulatório Neurovascular do Hospital de Clínicas de Porto Alegre (HCPA). Foi preenchida uma ficha de avaliação com dados da amostra e realizada a avaliação da espasticidade do MS, por meio da escala de Ashworth modificada (MAS), e da movimentação ativa da mão, por meio da escala de movimentação da mão (EMM). Para a correlação das variáveis, foi usado o coeficiente de correlação tau de Kendall, adotando-se um nível de significação de 5% (p≤0,05). Foram avaliados 47 sujeitos de ambos os sexos com média de idade de 64,5 (±13) anos e média de tempo de AVC de 2,7 (±1,8) meses. A moda da EMM foi de 6 pontos e 74,4% dos pacientes não eram espásticos. O movimento da mão apresentou correlação significativa negativa com as musculaturas espásticas avaliadas. Houve uma correlação negativa moderada com as musculaturas peitoral (r=−0,383; p=0,007), os flexores de cotovelo (r=−0,339; p=0,016) e pronadores (r=−0,460; p=0,001), e correlação negativa alta com os flexores de punho (r=−0,588; p<0,001) e os flexores de dedos (r=−0,692; p<0,001). Concluiu-se que quanto maior o grau de espasticidade do membro superior, menor a capacidade de movimentação da mão dos pacientes.

RESUMEN La hemiparesia y la espasticidad en los pacientes son consecuencias frecuentes del accidente cerebrovascular (ACV), lo que resulta en la dificultad del paciente para mover el hemicuerpo afectado. El objetivo de este estudio fue verificar la relación entre la espasticidad en el miembro superior (MS) y la capacidad de mover la mano de estos pacientes a partir de un estudio transversal, con un diseño correlacional ex post facto. Se evaluaron a pacientes en seguimiento en el Ambulatorio de Neurovascular del Hospital de Clínicas de Porto Alegre (HCPA), en Brasil. El formulario de evaluación se utilizó para recoger los datos de la muestra, y para el análisis de la espasticidad del MS se aplicó la escala de Ashworth modificada (MAS), y el movimiento activo de la mano, la escala de movimiento de la mano (EMM). Para la correlación de variables se utilizó el coeficiente de correlación tau de Kendall, con un nivel de significación del 5% (p≤0,05). Se evaluaron a 47 personas de ambos sexos, con una edad media de 64,5 (±13) años y un tiempo medio del ACV de 2,7 (±1,8) meses. La moda de EMM fue de 6 puntos, y el 74,4% de los pacientes no eran espásticos. El movimiento de la mano mostró una correlación negativa significativa con las musculaturas espásticas evaluadas. Hubo una moderada correlación negativa con la musculatura pectoral (r=−0,383; p=0,007), los flexores del codo (r=−0,339; p=0,016) y pronadores (r=−0,460; p=0,001), y una alta correlación negativa con los flexores de muñeca (r=−0,588; p<0,001) y los flexores de dedos (r=−0,692; p<0,001). Se concluyó que cuanto mayor es el grado de espasticidad del miembro superior, menor será la capacidad de movimiento de las manos de los pacientes.

ABSTRACT Hemiparesis and spasticity are common consequences in stroke patients, hampering the movement in the affected side. Our study aimed to correlate upper limb spasticity and the ability to move the hand in these patients. This is a quantitative cross-sectional study with an ex post facto correlational design. We evaluated patients undergoing follow-up at the Neurovascular Outpatient Clinic at the Hospital de Clínicas de Porto Alegre. An evaluation form was filled out with sample data and the upper limb spasticity was evaluated using the Modified Ashworth Scale and the active hand movement using the Hand Movement Scale. Correlation of variables were verified using Kendall's rank correlation coefficient. A significance level of 5% (p≤0.05) was adopted. In total, we evaluated 47 subjects of all genders, with a mean age of 64.5 (±13) years and a mean stroke time of 2.7 (±1.8) months. The Hand movement Scale mode was 6 points, and 74.4% of patients were not spastic. Hand movement showed a significant negative correlation with the spastic muscles evaluated. There was a moderate negative correlation with the pectoral muscles (r=−0.383; p=0.007), elbow flexors (r=−0.339; p=0.016) and pronators (r=−0.460; p=0.001) and high negative correlation with wrist flexors (r=−0.588; p<0.001) and finger flexors (r=−0.692; p<.001). The greater the degree of spasticity of the upper limb, the smaller the hand movement capacity in stroke patients.

Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A.

INTRODUCTION: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known. This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year. METHODS: We retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or Abobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated. RESULTS: This is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was 116 789.70. The mean annual cost per patient was 603.64 for onabotulinumtoxin A, 642.69 for abobotulinumtoxin A, and 707.59 for incobotulinumtoxin A. CONCLUSIONS: Our economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs.

Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A. / Análisis descriptivo de coste de tratamiento de la espasticidad con diferentes tipos de toxina botulínica A, a lo largo de un año.

INTRODUCTION: Botulinum toxin A is the first-line treatment for localised spasticity. However, the economic impact of this treatment is not fully known. This study aimed to describe the real costs of botulinum toxin A for the treatment of adult patients with spasticity at a spasticity clinic pertaining to a rehabilitation service, over a period of one year. METHODS: We retrospectively reviewed all medical procedures carried out during the year 2017. We collected data on the type of toxin used (incobotulinumtoxin A, onabotulinumtoxin A, or AAbobotulinumtoxin A), the number of units injected, the anatomical region, and the time elapsed between infiltrations. The costs of medication and indirect costs, such as staff and consumables, were also calculated. RESULTS: This is the first study to describe the real costs of botulinum toxin treatment of spasticity in adult patients in Spain. In 2017, 510 infiltration procedures were performed in 164 patients. The total cost of treating spasticity in our service was €116 789.70. The mean annual cost per patient was €603.64 for onabotulinumtoxin A, €642.69 for abobotulinumtoxin A, and €707.59 for incobotulinumtoxin A. CONCLUSIONS: Our economic study of real clinical practice is consistent with the theoretical models published in the literature. The different characteristics of each toxin and the inability to establish an equivalence between the units of each drug prevents us from directly comparing these costs.

Localization of the centre of the highest region of the triceps brachii muscle spindle abundance and its significance in muscle spasticity block / Localización del centro de la región más alta del huso del músculo tríceps braquial y su importancia en el bloqueo de la espasticidad muscular

SUMMARY: This study aimed to accurately localize the location and depth of the centre of the highest region of muscle spindle abundance (CHRMSA) of the triceps brachii muscle. Twenty-four adult cadavers were placed in the prone position. The curve connecting the acromion and lateral epicondyle of the humerus close to the skin was designed as the longitudinal reference line (L), and the curve connecting the lateral and the medial epicondyle of the humerus was designed as the horizontal reference line (H). Sihler's staining was used to visualize the dense intramuscular nerve region of the triceps brachii muscle. The abundance of muscle spindle was calculated after hematoxylin and eosin stain. CHRMSA was labelled by barium sulphate, and spiral computed tomography scanning and three- dimensional reconstruction were performed. Using the Syngo system, the projection points of CHRMSA on the posterior and anterior arm surface (P and P' points), the position of P points projected to the L and H lines (PL and PH points), and the depth of CHRMSA were determined. The PL of the CHRMSA of the long, medial, and lateral heads of the triceps brachii muscle were located at 34.83 %, 75.63 %, and 63.93 % of the L line, respectively, and the PH was located at 63.46 %, 69.62 %, and 56.07 % of the H line, respectively. In addition, the depth was located at 34.73 %, 35.48 %, and 35.85 % of the PP' line, respectively. These percentage values are all the means. These body surface locations and depths are suggested to be the optimal blocking targets for botulinum toxin A in the treatment of triceps brachii muscle spasticity.

RESUMEN: Este estudio tuvo como objetivo localizar con precisión la ubicación y la profundidad del centro de la región más alta del huso muscular (CHRMSA) del músculo tríceps braquial. Se colocaron veinticuatro cadáveres adultos en posición prona y se designó la curva que conecta el acromion y el epicóndilo lateral del húmero cerca de la piel como la línea de referencia longitudinal (L), y la curva que conecta los epicóndilos lateral y medial del húmero fue designada como la línea de referencia horizontal (H). Se usó la tinción de Sihler para visualizar la región nerviosa intramuscular densa del músculo tríceps braquial. La abundancia de huso muscular se calculó después de la tinción con hematoxilina y eosina. CHRMSA se marcó con sulfato de bario y se realizó una tomografía computarizada espiral y una reconstrucción tridimensional. Usando el sistema Syngo, fueron determinados los puntos de proyección de CHRMSA en la superficie posterior y anterior del brazo (puntos P y P'), la posición de los puntos P pro- yectados en las líneas L y H (puntos PL y PH) y la profundidad de CHRMSA. Los PL de la CHRMSA de las cabezas larga, medial y lateral del músculo tríceps braquial se ubicaron en el 34,83 %, 75,63 % y 63,93 % de la línea L, respectivamente, y el PH se ubicó en el 63,46 %, 69,62 %, y 56,07 % de la línea H, respectivamente. La profundidad se ubicó en el 34,73 %, 35,48 % y 35,85 % de la línea PP', respectivamente. Estos valores porcentuales son todas las medias. Se sugiere que estas ubicaciones y profundidades de la superficie corporal son los objetivos de bloqueo óptimos para la toxina botulínica A en el tratamiento de la espasticidad del músculo tríceps braquial.

Protocolo de sedación con sevoflurano para la infiltración de toxina botulínica tipo A en parálisis cerebral infantil / Sevoflurane sedation protocol in children with cerebral palsy undergoing botulinum toxin-A injections

Objetivo Describir nuestra experiencia con un protocolo basado en el uso de sevoflurano para la sedación y analgesia durante la infiltración de toxina botulínica tipo A (BoNT-A), en niños con parálisis cerebral (PC), especialmente en términos de seguridad y eficacia. Material y métodos Estudio observacional retrospectivo de pacientes con PC a los que se realizó infiltración con BoNT-A bajo sedación con sevoflurano desde noviembre de 2012 hasta diciembre de 2019. Se revisaron las características demográficas, las características clínicas y funcionales, la efectividad de la sedación, los eventos adversos (EA) y la satisfacción del profesional. Resultados Se realizaron 387 sedaciones en 74 pacientes diagnosticados de PC. La sedación efectiva se logró en el 100% de los procedimientos, facilitando la colaboración durante la infiltración y la satisfacción del profesional. Se notificaron EA en el 6,02% de los procedimientos, siendo los más frecuentes las náuseas y los vómitos (3,88%) y la hipoxemia transitoria (2,07%). No se informaron EA graves. No se encontró asociación entre la incidencia de EA y las variables clínicas, funcionales o el riesgo antes de la anestesia. Conclusiones La sedación con sevoflurano muestra resultados prometedores en términos de seguridad y efectividad para el manejo de la agitación y el dolor durante la infiltración de BoNT-A en nuestra práctica clínica diaria. Además, puede facilitar la infiltración, permitir la exploración bajo sedación e infiltración multinivel con buena tolerancia (AU)

Objective This study aimed to describe our experience with a protocol based on sevoflurane sedation to control pain and agitation during botulinum toxin-A (BoNT-A) infiltration in children with cerebral palsy (CP), especially in terms of safety and efficacy. Material and methods We conducted a retrospective observational study of patients diagnosed with CP who underwent BoNT-A infiltration with sevoflurane sedation from November 2012 to December 2019. Demographic, clinical and functional characteristics, the effectiveness of sedation, adverse events (AE) and professional satisfaction were reviewed. Results A total of 387 sedations were successfully performed in 74 patients. Effective sedation was achieved in 100% of procedures, facilitating collaboration during infiltration and improving professional satisfaction. AE were reported in 6.02% of the procedures, the most frequent being nausea and vomiting (3.88%) and transient hypoxemia (2.07%). There were no severe AE. No association was found between the incidence of AE and the clinical and functional variables or risk before anaesthesia. Conclusion Sevoflurane sedation shows promising results in terms of safety and effectiveness for the management of agitation and pain during BoNT-A infiltration in our daily clinical practice. In addition, it can facilitate infiltration, allowing examination under sedation and multilevel infiltration with good tolerance (AU)

Ondas de choque. Evidencias y recomendaciones SETOC (Sociedad Española de Tratamientos con Ondas de Choque) / Current evidences in shockwave treatment. SETOC (Spanish Society of Shockwave Treatment) recommendations

El documento consenso SETOC muestra la evidencia científica de la tecnología en ondas de choque extracorpóreas (OCE) y ondas de presión radial (OPR) en diversidad de patologías musculoesqueléticas, cutáneas, espasticidad, urológicas, etc. Las OCE y las OPR son un tratamiento eficaz, seguro, no invasivo, coste-efectivo, bien tolerado por el paciente, sin necesidad de anestesia, que reduce la necesidad de cirugía, con menor riesgo de complicaciones y menor tiempo de recuperación que una cirugía. Por todo ello, las OCE y las OPR deberían ser la primera opción terapéutica de las patologías crónicas mencionadas, cuando las alternativas conservadoras hayan fallado, teniendo en cuenta las recomendaciones de este artículo, de las sociedades científicas y de la evidencia para cada tecnología (AU)

This SETOC consensus document shows the scientific evidence of the technology in shockwaves (SW) and radial pressure waves (RPW) in a variety of spasticity disorders, musculoskeletal, skin, urological diseases, etc. SW and RPW, without anesthesia, are an effective, safe, non-invasive, cost-effective treatment, which reduces the need for surgery, lower risk of complications, faster recovery and greater acceptability to patients than surgery. Consequently, SW and RPW should be the first therapeutic option in the aforementioned chronic pathologies, when conservative alternatives have failed. SETOC advises to follow the recommendations given in this article, including the ones given by SW scientific societies and best evidence for each technology as well (AU)

The efficacy of immediate implantation of macroporous poly(N-[2-hydroxypropyl]-methacrylamide) hydrogel after laceration spinal cord injury in young rats / Eficacia de la implantación inmediata de hidrogel macroporoso de poli (N- [2-hidroxipropil] - metacrilamida) después de una lesión de la médula espinal en ratas jóvenes

SUMMARY: Spinal cord regeneration after mechanical injury is one of the most difficult biomedical problems. This article evaluates the effect of poly(N-[2-hydroxypropyl]-methacrylamide) hydrogel (PHPMA-hydrogel) on spinal cord regeneration in young rats after lateral spinal cord hemi-excision (laceration) at the level of segments T12-T13 (TrGel group). The locomotor function score (FS) and the paretic hindlimb spasticity score (SS) were assessed according to Basso-Beattie-Bresnahan (BBB) and Ashworth scales, respectively, and compared to a group of animals with no matrix implanted (Tr group). Regeneration of nerve fibers at the level of injury was evaluated at ~5 months after spinal cord injury (SCI). One week after the SCI induction, the FS on the BBB scale was 0.9±0.5 points in the Tr group and 3.6±1.2 points in the TrGel group. In the Tr group, the FS in 5 months was significantly lower than in 2 weeks after SCI, while no significant changes in FS were detected in the TrGel group over the entire observation period. The final FS was 0.8±0.3 points in the Tr group and 4.5±1.8 points in the TrGel group. No significant changes in SS have been observed in the TrGel group throughout the experiment, while the Tr group showed significant increases in SS at 2nd week, 6th week, 3th month and 5th month. The SS in 5 months was 3.6±0.3 points on the Ashworth scale in the Tr group and 1.8±0.7 points in the TrGel group. Throughout the observation period, significant differences in FS between groups were observed only in 5 weeks after SCI, whereas significant differences in SS were observed in 2, 3 and 6-8 weeks post-injury. Glial fibrous tissue containing newly formed nerve fibers, isolated or grouped in small clusters, that originated from the surrounding spinal cord matter have been found between the implanted hydrogel fragments. In conclusion, PHPMA-hydrogel improves recovery of the hindlimb locomotor function and promotes regenerative growth of nerve fibers. Further research is needed to clarify the mechanism of this PHPMA-hydrogel effect.

RESUMEN: La regeneración de la médula espinal después de una lesión mecánica es uno de los problemas biomédicos más difíciles. Este artículo evalúa el efecto del hidrogel de poli (N- [2-hidroxipropil] -metacrilamida) (PHPMA-hidrogel) sobre la regeneración de la médula espinal en ratas jóvenes después de la hemiescisión lateral de la médula espinal (lesión) a nivel de los segmentos T12 - T13 (Grupo TrGel). La puntuación de la función locomotora (FS) y la puntuación de espasticidad parética de las patas traseras (SS) se evaluaron de acuerdo con las escalas de Basso- Beattie-Bresnahan (BBB) y Ashworth, respectivamente, y se compararon con un grupo de animales sin matriz implantada (grupo Tr). Se evaluó la regeneración de las fibras nerviosas al nivel de la lesión ~ 5 meses después de la lesión de la médula espinal (LME). Una semana después de la inducción de SCI, el FS en la escala BBB fue 0,9 ± 0,5 puntos en el grupo Tr y 3,6 ± 1,2 puntos en el grupo TrGel. En el grupo Tr, el FS en 5 meses fue significativamente menor que en 2 semanas después de SCI, mientras que no se detectaron cambios significativos en FS en el grupo TrGel durante el período de observación. El FS final fue de 0,8 ± 0,3 puntos en el grupo Tr y de 4,5 ± 1,8 puntos en el grupo TrGel. No se han obser- vado cambios significativos en SS en el grupo TrGel durante el experimento, mientras que el grupo Tr mostró aumentos significativos en SS en la 2ª semana, 6ª semana, 3º mes y 5º mes. La SS en 5 meses fue de 3,6 ± 0,3 puntos en la escala de Ashworth en el grupo Tr y de 1,8 ± 0,7 puntos en el grupo TrGel. A lo largo del período de observación, se observaron diferencias significativas en FS entre los grupos solo en 5 semanas después de la LME, mientras que se observaron diferencias significativas en SS en 2, 3 y 6-8 semanas después de la lesión. Entre los fragmentos de hidrogel implantados se observó tejido fibroso glial que contenía fibras nerviosas recién formadas, aisladas o agrupadas en pequeños grupos, que se originaban a partir de la materia de la médula espinal circundante. En conclusión, PHPMA-hydrogel mejora la recuperación de la función locomotora de las patas traseras y promueve el crecimiento regenerativo de las fibras nerviosas. Se requieren más estudios para aclarar el mecanismo del efecto de hidrogel PHPMA.

Distribución de patrones espásticos en extremidad superior posterior a un daño de motoneurona superior / Distribution of spastic patterns in upper extremity after an upper motor neuron syndrome

ANTECEDENTES: la evidencia sobre personas que presentan daño de motoneurona superior y desarrollan un patrón de espasticidad en extremidad superior (EES) es limitada. Este signo positivo de disfunción o secundario al daño de la motoneurona superior se asocia con pérdida de función y disminución de la independencia, provocando discapacidad y alterando la calidad de vida. OBJETIVO: determinar la distribución de frecuencias de los patrones de EES, muñeca, dedos y pulgar posterior a un daño de motoneurona superior. MÉTODO: diseño descriptivo de corte transversal prospectivo. Se realizó una medición a 206 sujetos pertenecientes a 17 centros de salud, quienes cumplieron con los criterios de inclusión y firmaron el consentimiento. La evaluación incluyó datos clínicos y la evaluación del patrón de EES (Clasificación de Hefter), muñeca, dedos (Zancolli adaptado) y pulgar (Clasificación de House). RESULTADOS: El análisis consideró cada una de las taxonomías de los patrones de EES evaluados (Hefter I a V). La distribución de frecuencias fue investigada mediante la prueba χ2 de bondad de ajuste, seguida de la inspección post hoc de los residuos estandarizados (z) en cada celda. Se identificaron frecuencias significativamente mayores en: el patrón III de extremidad superior, el patrón cubitalizado neutro de muñeca, el patrón del flexor profundo y mixto de Zancolli adaptado, y en los patrones 3, 4 del pulgar. Ninguna taxonomía se asoció al tiempo de evolución y tipo de ACV. CONCLUSIÓN: El estudio aporta evidencia relevante sobre la distribución frecuencia de patrones espásticos, posterior a un daño de motoneurona superior. La información proporcionada busca apoyar el proceso de decisión terapéutica potenciando la recuperación funcional de la extremidad superior.

BACKGROUND: The evidence regarding people who present superior motor neuron damage and develop a pattern of spasticity in the upper limb (SUL) is limited. This positive sign of the superior motor neuron is associated with both the loss of function and the decreased independence, causing disability and altering life quality. OBJECTIVE: to determine the frequency distribution of SUL, wrist, finger and thumb patterns after superior motor neuron damage. METHOD: prospective cross-sectional descriptive design, the sample consisted of 206 patients belonging to 17 health centers, who met the inclusion criteria and signed the informed consent, approved by the committee of ethics. The study considered a measurement, including clinical data and evaluation of the pattern of SUL (Hefter´s classification), wrist, fingers (adapted Zancolli) and thumb (House Classification). RESULTS: The analysis considered each of the taxonomies of evaluated patterns (Hefter´s I-V). Frequency distribution was investigated by χ2 goodness of fit tests, followed by post hoc inspection of standardized residues (z) in each cell. Significantly higher frequencies were identified in the upper limb pattern III, the neutral cubitalized wrist pattern, the adapted Zancolli deep flexor pattern and in the thumb patterns 3, 4. No taxonomy was associated with the evolution time and type of stroke. CONCLUSION: The study provides with relevant scientific evidence regarding the frequency distribution of spasticity patterns after superior motor neuron damage. The information provided can support the therapeutic decision process by enhancing the functional recovery of upper limb.

Tratamiento con toxina botulínica en niños con parálisis cerebral espástica. Análisis del tratamiento en tríceps sural durante 2017-2018 en el / Centro de Rehabilitación Infantil Teletón, Uruguay / Botulinum toxin in the treatment of children with spastic cerebral palsy. Analysis of sural tricep therapy during 2017-2018 at the Teletón Children's Rehabilitation Center, Uruguay / Tratamento com toxina botulínica em crianças com paralisia cerebral espástica. Análise do tratamento do tríceps sural durante 2017-2018 no Centro de Rehabilitación Infantil Teletón, Uruguai

Resumen: Introducción: la parálisis cerebral (PC) es la causa más frecuente de discapacidad motriz en niños y adolescentes. En el 85% de los casos, la manifestación motora predominante es la espasticidad. Las inyecciones de toxina botulínica tipo A (TB-A) se han usado para reducir la espasticidad en niños con PC. No existen investigaciones a nivel nacional que comprueben si los resultados son comparables a los reportados en la literatura. Objetivo: determinar el efecto del tratamiento con TB-A en el tríceps sural en conjunto con la rehabilitación física en niños con PC espástica durante los años 2017-2018 en el Centro de Rehabilitación Infantil Teletón, Uruguay. Métodos: se realizó un estudio descriptivo, retrospectivo, de cohorte histórica única con seguimiento longitudinal, mediante la revisión de historias clínicas de los pacientes con PC con marcha independiente o asistida que recibieron tratamiento con TB-A para el tratamiento de la espasticidad del tríceps sural durante el período 2017-2018. Resultados: se analizaron 40 procedimientos de inyección de TB-A. Se observó una buena respuesta al mes y a los 3 meses del tratamiento con TB-A, con mejoría del ángulo de dorsiflexión del pie con la rodilla en flexión y en extensión, mejoría del puntaje de la escala de espasticidad de Ashworth modificada y, en el 95% de los procedimientos, de la percepción subjetiva de los padres. Se observó una disminución del efecto hacia los 6 meses de la aplicación. Conclusión: la aplicación de TB-A en el Centro Teletón muestra resultados positivos, comparables con los reportados en la bibliografía internacional.

Abstract: Introduction: cerebral palsy (CP) is the most common source of motor disability in children and adolescents. In 85% of cases, the prevailing motor manifestation is spasticity. Botulinum toxin Type A injections (TB-A) have been used to reduce spasticity in children with cerebral palsy (CP). There are no studies at the national level that show whether the results are comparable to those reported in literature. Objective: to determine the effect of TB-A therapy in the triceps surae along with the physical rehabilitation in children with spastic cerebral palsy (CP) during 2017-2018 at the Teleton Children´s Rehabilitation Center, Uruguay. Method: retrospective, descriptive study of a single cohort with a longitudinal follow-up was conducted, through the review of medical records belonging to patients with CP with independent or assisted gait, who received TB-A therapy to treat sural triceps spasticity during 2017-2018. Results: 40 TB-A injection procedures were analysed. A good response was observed one month and three months after being treated with TB-A, evidencing improvement in the dorsiflexion angle between the foot and the knee in flexion and extension, improvement on the modified Ashworth spasticity scale score and, in 95% of procedures, the subjective perception of parents. The effect was observed to decrease towards 6 months after the procedure. Conclusion: application of TB-A at the Teletón Center shows positive results, comparable to those reported by international blibliography.

Resumo: Introdução: a paralisia cerebral (PC) é a causa mais freqüente de deficiência motora em crianças e adolescentes. Em 85% dos casos, a manifestação motora predominante é a espasticidade. As injeções de toxina botulínica tipo A (TB-A) têm sido usadas para reduzir a espasticidade em crianças com PC. Não há pesquisas nacionais que verifiquem se os resultados são comparáveis aos relatados na literatura. Objetivo: determinar o efeito do tratamento da TB-A no tríceps sural em conjunto com a reabilitação física em crianças com PC espástica durante os anos 2017-2018 no Centro de Rehabilitación Infantil Teletón, Uruguai. Métodos: estudo descritivo, retrospectivo, com coorte histórica única com acompanhamento longitudinal, realizado por meio da revisão de prontuários de pacientes com PC com deambulação independente ou assistida que receberam tratamento com TB-A para o tratamento da espasticidade do tríceps sural, no período 2017-2018. Resultados: 40 procedimentos de injeção de TB-A foram analisados. Observou-se boa resposta um mês e três meses após o tratamento com TB-A, com melhora no ângulo de dorsiflexão do pé com o joelho em flexão e extensão, melhora no escore da escala de espasticidade de Ashworth modificada e, em 95% dos procedimentos, a partir da percepção subjetiva dos pais. Uma diminuição no efeito foi observada 6 meses após a aplicação. Conclusão: a aplicação do TB-A no Centro de Rehabilitación Infantil Teletón apresentou resultados positivos, comparáveis aos relatados na literatura internacional.